Sonnet BioTherapeutics is no longer just a cancer drug developer. Its $888 million merger will place it among the largest HYPE holders, blurring the lines between traditional finance and decentralized protocols in a high-stakes treasury experiment. According to a July…
Related Posts
South Korea’s largest bank brings cross-border payments to Kinexys
KB Kookmin Bank will use JPMorgan’s Kinexys for near-real-time U.S. dollar payments across 10 countries, starting in August…
AI could’ve predicted—even prevented—the Mantra crash | Opinion
While blockchain promises decentralization and transparency, it remains vulnerable without advanced AI-powered risk management systems
Whales short XRP, DOGE and PEPE ahead of Powell speech
As FED Chair Jerome Powell’s speech on the U.S. economic outlook looms ahead, whales are bracing themselves for…